-+ 0.00%
-+ 0.00%
-+ 0.00%

Zhitong Finance App News, Mengke Pharmaceutical (688373.SH) announced that the company plans to separately sign an exclusive license agreement for the MRX-23 (an antibody drug conjugate under development by the company) project (“MRX-23 License Agreement”) and a licensor platform technical cooperation agreement (“Platform Cooperation Agreement”) with Swiss ClearIdeBio Therapeutics AG (“ClearIDEbio”). The former involves an exclusive global license for the MRX-23 project; the latter is a multi-project option cooperation based on the company's new camptothecin-loaded “STOPIN” antibody-conjugated drug (ADC) platform. ClearIDEbio can exercise the right to choose an agreed number of targets or target combinations (up to 6, “related projects” for short) as agreed by agreement.

Zhitongcaijing·10/09/2026 12:57:07
Listen to the news
Zhitong Finance App News, Mengke Pharmaceutical (688373.SH) announced that the company plans to separately sign an exclusive license agreement for the MRX-23 (an antibody drug conjugate under development by the company) project (“MRX-23 License Agreement”) and a licensor platform technical cooperation agreement (“Platform Cooperation Agreement”) with Swiss ClearIdeBio Therapeutics AG (“ClearIDEbio”). The former involves an exclusive global license for the MRX-23 project; the latter is a multi-project option cooperation based on the company's new camptothecin-loaded “STOPIN” antibody-conjugated drug (ADC) platform. ClearIDEbio can exercise the right to choose an agreed number of targets or target combinations (up to 6, “related projects” for short) as agreed by agreement.